NCT03697655Unknown2 期
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)
Polish Myeloma Consortium2 个研究点 分布在 1 个国家目标入组 274 人开始时间: 2018年12月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 274
- 试验地点
- 2
- 主要终点
- Event Free Survival (ESF)
研究概览
简要总结
PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).
详细描述
The study is composed of two phase 2 randomized multi-center substudies:
- PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical relapse
- PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD) reappearance
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosed symptomatic MM who have completed one or two prior lines of therapy; single or tandem autologous stem cell transplant is not considered a separate line of therapy and is not mandatory; and have achieved at least PR to last line of therapy, and who experience asymptomatic biochemical progression not meeting criteria for SPR.
- •Males and females ≥18 years of age.
- •Life expectancy of more than 3 months.
- •ECOG performance status of 0-
- •Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
- •ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
- •Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
- •Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential.
- •FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
- •Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- •Voluntary written informed consent.
排除标准
- •Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG criteria.
- •Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by < 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by < 2 months.
- •Patients who have already started or received post-transplant maintenance or consolidation treatment.
- •Subject has received daratumumab or other anti-CD38 therapies previously.
- •Patients not able to tolerate daratumumab or required concomitant medication and procedures.
- •Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal.
- •Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
- •POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
- •Plasma cell leukemia.
- •Waldenström's macroglobulinemia.
- •CNS involvement.
- •Pregnant or lactating females.
- •Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
- •Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
- •Myocardial infarction within 3 months prior to enrollment, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- •Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening.
- •Patient who in investigator's opinion is unable to comply with the protocol requirements.
- •Uncontrolled hypertension or diabetes.
- •Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to enter the study.
- •Active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
- •Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone.
- •Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
- •PREDATOR-MRD:
- •Inclusion Criteria:
- •Patients with diagnosed symptomatic MM who have completed one or two prior lines of therapy; single or tandem autologous stem cell transplant is not considered a separate line of therapy and is not mandatory; and have achieved CR with negative MRD to the last line of therapy and who remain in CR MRD negative. The last response assessment confirming CR MRD negative status based on assessment of bone marrow sample using flow cytometry with sensitivity of at least 10-5 needs to be performed not earlier than 3 months before inclusion to the study.
- •Males and females ≥18 years of age.
- •Life expectancy of more than 3 months.
- •ECOG performance status of 0-
- •Adequate hepatic function, with bilirubin ≤1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.
- •ANC ≥1.0 x 109/L, hemoglobin ≥8 g/dL, platelet count ≥75 x 109/L.
- •Calculated creatinine clearance (by Cockroft-Gault) ≥50 mL/min (this equation is as follows: Creatinine clearance in ml/min: (140 - age) x body weight (kg) / 72 x plasma creatinine (mg/dL); multiplied by 0.85 for women) or serum creatinine below 2 g/dL.
- •Negative pregnancy test (serum βHCG) for women of childbearing potential (including pre-menopausal women who have had a tubal ligation) and for all women not meeting the definition of postmenopausal (≥ 24 months of amenorrhea), and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy. For all other women, documentation must be present in medical history confirming that the patient is not of childbearing potential
- •FCBP must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the study.
- •Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- •Voluntary written informed consent.
- •Exclusion criteria:
- •Potential subjects with evidence of progressive disease (CRAB symptoms) as per IMWG criteria.
- •Patient with SPR - significant paraprotein relapse defined as doubling of the M-component in two consecutive measurements separated by < 2 months; or an increase in the absolute levels of serum M protein by 1g/dl, or urine M protein by 500mg /24h, or involved serum FLC level by 20mg/dl (plus an abnormal FLC ratio) in two consecutive measurements separated by < 2 months.
- •Patients who have already started or received post-transplant maintenance or consolidation treatment.
- •Subject has received daratumumab or other anti-CD38 therapies previously.
- •Patients not able to tolerate daratumumab or required concomitant medication and procedures.
- •Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal.
- •Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study).
- •POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
- •Plasma cell leukemia.
- •Waldenström's macroglobulinemia.
- •CNS involvement.
- •Pregnant or lactating females.
- •Radiotherapy within 14 days before randomization. Seven days may be considered if to single area.
- •Major surgery within 3 weeks prior to first dose. Kyfoplasty is not considered as a major surgery.
- 另有 8 项未显示
研究组 & 干预措施
PREDATOR-BR Cohort A
Experimental
n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
干预措施: Daratumumab 20 MG/ML [Darzalex] (Drug)
PREDATOR-MRD Cohort A
Experimental
n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
干预措施: Daratumumab 20 MG/ML [Darzalex] (Drug)
结局指标
主要结局
Event Free Survival (ESF)
时间窗: from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks
To compare (EFS) between daratumumab arm and observation arm after randomization of patients with biochemical relapse of Multiple Myeloma and MRD reappearance in Multiple Myeloma
次要结局
- Overall Response Rate(from randomization till progression or death from any cause, up to 129 weeks)
- Overall Survival(throughout the duration of the study, no longer than 6 years)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance or biochemical relapse is effective in preventive therapy.Multiple Myeloma and Minimal Residual DiseaseMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-003253-41-PLPolish Myeloma Consortium274
招募中
1 期
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell TransplantMyelodysplastic SyndromesNCT04742634Washington University School of Medicine209
进行中（未招募）
1 期
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantInfiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid VariantRenal Pelvis Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage II Urethral Cancer AJCC v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Renal Pelvis Cancer AJCC v7Stage III Ureter Cancer AJCC v7Stage III Urethral Cancer AJCC v7Stage IV Renal Pelvis Cancer AJCC v7Stage IV Ureter Cancer AJCC v7Stage IV Urethral Cancer AJCC v7Ureter Urothelial CarcinomaUrethral Urothelial CarcinomaHydronephrosisNCT02812420M.D. Anderson Cancer Center54
已完成
2 期
Short Course Daratumumab in Patients With Multiple MyelomaMultiple MyelomaNCT03490344Memorial Sloan Kettering Cancer Center10
已完成
早期 1 期
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor PositivePrognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8NCT03132467M.D. Anderson Cancer Center16